Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer

Simple Summary Prostate cancer is the most common non-cutaneous malignancy among men in the United States. Bone metastases and health are crucial issues in prostate cancer patient management. The aim of our review was to summarize the novel therapeutic targets of prostate cancer with bone metastasis, including treatments to palliate pain and therapies to prevent complications of osseous metastasis. Additionally, our study offers a comprehensive overview of the research on bone metastases in prostate cancer, which can be a valuable resource for researchers in the field.Abstract In the absence of early detection and initial treatment, prostate cancer often progresses to an advanced stage, frequently spreading to the bones and significantly impacting patients' well-being and healthcare resources. Therefore, managing patients with prostate cancer that has spread to the bones often involves using bone-targeted medications like bisphosphonates and denosumab to enhance bone structure and minimize skeletal complications. Additionally, researchers are studying the tumor microenvironment and biomarkers to understand the mechanisms and potential treatment targets for bone metastases in prostate cancer. A literature search was conducted to identify clinical studies from 2013 to 2023 that focused on pain, performance status, or quality of life as primary outcomes. The analysis included details such as patient recruitment, prior palliative therapies, baseline characteristics, follow-up, and outcome reporting. The goal was to highlight the advancements and trends in bone metastasis research in prostate cancer over the past decade, with the aim of developing strategies to prevent and treat bone metastases and improve the quality of life and survival rates for prostate cancer patients.